Scarica l'app Stockscreener
18.93
10.95%
1.95
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
What machine learning models say about Zenas BioPharma Inc.2025 Volatility Report & Growth Focused Entry Point Reports - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.2025 Institutional Moves & Consistent Growth Stock Picks - Newser
What MACD and RSI say about Zenas BioPharma Inc.Portfolio Growth Summary & Daily Growth Stock Tips - Newser
Is Zenas BioPharma Inc.’s growth already priced in2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - khodrobank.com
Real time breakdown of Zenas BioPharma Inc. stock performanceRecession Risk & Precise Buy Zone Tips - Newser
Royalty Pharma's Strategic Position in the Biopharma Royalty Space - AInvest
Using fundamentals and technicals on Zenas BioPharma Inc.July 2025 Outlook & Growth Oriented Trade Recommendations - Newser
Technical signs of recovery in Zenas BioPharma Inc.Weekly Stock Report & Weekly Setup with High ROI Potential - Newser
Is Zenas BioPharma Inc. still a buy after recent gainsWeekly Investment Report & Reliable Entry Point Trade Alerts - beatles.ru
How moving averages guide Zenas BioPharma Inc. tradingWeekly Trade Recap & Precise Trade Entry Recommendations - Newser
Chart based exit strategy for Zenas BioPharma Inc.Weekly Market Report & Weekly Top Gainers Alerts - Newser
Will Zenas BioPharma Inc. price bounce be sustainable2025 Fundamental Recap & Accurate Entry/Exit Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsGap Down & Community Driven Trade Alerts - Newser
What’s the RSI of Zenas BioPharma Inc. stock2025 Geopolitical Influence & Verified Swing Trading Watchlists - khodrobank.com
Is Zenas BioPharma Inc. stock overvalued or fairly pricedJuly 2025 Catalysts & Short-Term Swing Trade Alerts - khodrobank.com
Can Zenas BioPharma Inc. hit a new high this month2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - khodrobank.com
Zenas Biopharma shares fall 2.28% intraday as Royalty Pharma announces $2.0 billion offering. - AInvest
Pattern recognition hints at Zenas BioPharma Inc. upside2025 Retail Activity & Weekly High Momentum Picks - Newser
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Published on: 2025-09-03 01:34:16 - Newser
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Tick level data insight on Zenas BioPharma Inc. volatility2025 Momentum Check & Expert Curated Trade Ideas - Newser
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Bolt Projects Holdings, Inc. shares rise 1.54% premarket after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Zenas BioPharma Secures $300M Funding for Obexelimab - TipRanks
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
Zenas BioPharma, Royalty Pharma Partner for $300mln Obexelimab Funding Agreement - AInvest
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab - StreetInsider
Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch - AInvest
Zenas BioPharma, Inc. and Royalty Pharma Enter into Obexelimab Funding Agreement for Up to $300 Million - MarketScreener
Quantitative breakdown of Zenas BioPharma Inc. recent moveEarnings Risk Report & Real-Time Volume Spike Alerts - Newser
Does Zenas BioPharma Inc. show high probability of reboundWeekly Risk Report & AI Forecast Swing Trade Picks - Newser
Will Zenas BioPharma Inc. outperform its industry peersWeekly Profit Analysis & Smart Investment Allocation Tips - khodrobank.com
Does Zenas BioPharma Inc. stock benefit from AI growthTrade Risk Report & Precise Buy Zone Tips - khodrobank.com
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):